Showing all 3 results
Daclatasvir Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Dihydrochloride Salt Tablet, packed exclusively in highly secure, moisture-resistant heavy-gauge HDPE bottles or Alu-Alu blister strips to ensure the absolute chemical survival of the active virological agent.
Active Ingredient Strength Primary Clinical Function Daclatasvir Dihydrochloride USP/Ph.Eur. 60 mg The Standard Eradication Macrodose: The definitive, globally standardized daily therapeutic payload utilized for the vast majority of patients to achieve a Sustained Virologic Response (SVR12 – Clinical Cure). Daclatasvir Dihydrochloride USP/Ph.Eur. 30 mg The CYP3A4 Titration Unit: The strict, mandatory dose-reduction unit utilized for patients who are co-infected with HIV and taking strong CYP3A inhibitors (like Ritonavir or Atazanavir). Excipients Anhydrous Lactose / Microcrystalline Cellulose / Croscarmellose Sodium / Silicon Dioxide / Magnesium Stearate / Premium Polymeric Film (Opadry Green) Diluent / Densifier / Superdisintegrant / Glidant / Heavy Film-Coating (Engineered specifically utilizing advanced dissolution-enhancing matrices to ensure the Dihydrochloride salt separates perfectly in gastric fluid, guaranteeing maximum systemic bioavailability) *Pack Sizes: Heavy-Gauge HDPE Bottles of 28 (Optimized exactly for a 4-week supply in strict 12-week or 24-week curative regimens).
Sofosbuvir 400 mg tablet + Ledipasvir 90 mg Tablet
FreeA tablet containing Sofosbuvir 400 mg + Ledipasvir 90 mg is a fixed-dose combination antiviral medication used to treat chronic Hepatitis C Virus (HCV) infection, specifically targeting genotypes 1, 4, 5, and 6.
Sofosbuvir 400mg+ Velpatasvir 100 mg Tablet
FreeA Sofosbuvir 400 mg + Velpatasvir 100 mg tablet is a fixed-dose combination antiviral medication used to treat chronic Hepatitis C Virus (HCV) infection across all major genotypes (1 through 6).
